The extracellular matrix (ECM) is a major determinant of the structural integrity and functional properties of the myocardium in common pathological conditions, and changes in vasculature contribute to cardiac dysfunction. Collagen (Col) XV is preferentially expressed in the ECM of cardiac muscle and microvessels.
T he extracellular matrix (ECM) has an important role in cardiac remodeling, defined by the adaptive changes in left ventricular structure, geometry, and function that follow cardiovascular stress in hypertensive heart disease, cardiomyopathies, or myocardial infarction and also as a function of age. 1 Degradation of myocardial collagens results in decreased ventricular stiffness and dilatation, whereas an increase in the total interstitial collagen content and crosslinking results in a stiffer myocardium and ventricular diastolic dysfunction. 2 Cardiomyopathy may result from a variety of acquired or genetic factors. In the absence of coronary artery disease, a significant proportion of cardiomyopathies are attributable to a genetic cause, eg, hereditary forms are present in approxi-mately 30% to 50% of patients experiencing dilative cardiomyopathy (DCM), and mutations in more than 30 genes have been linked to this disease. 3 Many defects in cytoskeletal and sarcomeric proteins involved in cardiomyocyte contraction and force production have been associated with familial DCM, but most of the genetic defects and pathophysiological mechanisms have still not been identified. 4 Recent studies using genetically modified mice suggest that altered cell-ECM interactions and cell-cell adhesion via the intercalated discs may be involved in DCM pathogenesis. [5] [6] [7] [8] Despite the well-characterized role of the ECM in cardiac remodeling, mutations in genes encoding ECM constituents have not been identified as a primary cause of DCM in humans.
The cardiac ECM consists mainly of the fibrillar collagen types I and III, and of smaller amounts of other interstitial matrix and basement membrane (BM) components, including elastin, fibronectin, laminins, and various proteoglycans. Collagen (Col) XV is predominantly located in the BM zones of microvessels and cardiac and skeletal myocytes. 9, 10 It is characterized by a highly interrupted collagenous domain flanked by large globular domains 11 and attached glycosaminoglycan chains, thus also being identified as a chondroitin sulfate proteoglycan. 12 The resulting molecular structure is unique among the collagens, being able to self-assemble into higher-order cruciform structures with intermolecular binding sites. 13, 14 Col XV can bind to BMs and microfibrillar components, including fibulin-2, nidogen-2, vitronectin, laminin, and fibronectin. 13, 16 In view of its location in the outermost layer of the lamina densa and close to the interstitial collagen fibers near the BMs, 17 it has been suggested that it may form a bridge between the fibrillar collagen matrix and the BMs 14, 17 and that it may act as a "molecular shock absorber" to stabilize and enhance resilience to compressive and expansive forces. 14 Moreover, the C-terminal noncollagenous part of Col XV (restin) has an antiangiogenic effect. 18 We have found previously that Col XV deficiency in mice induces a form of cardiac dysfunction characterized by a blunted contractile response to stimulation with the ␤-receptor agonist isoproterenol in isolated and perfused hearts. 19 In addition to a diminished inotropic response, microscopic analysis revealed abnormalities encompassing the microvessels and their endothelium. It has remained unknown on the basis of the previous data how these findings relate to in vivo cardiac and vascular functions and whether the lack of Col XV affects cardiac responses to hypertensioninduced fibrosis, left ventricular hypertrophy, and heart dysfunction. To date, no human disease-causing mutations in the COL15A1 gene have been identified, although increased deposition of Col XV has been observed in fibrotic kidneys, 10 suggesting that Col XV may have a role in ECM remodeling in pathological conditions. It has been unclear, however, whether Col XV may play a direct role in fibrotic processes.
Collectively, these previous studies have suggested a role for Col XV in the cardiovascular system and in morphogenesis and functions of the cardiovascular ECM. Therefore, we set out here to characterize the tissue structures and in vivo cardiovascular properties of Col15a1 Ϫ/Ϫ mice under basal conditions and after experimental hypertension. A wide array of approaches was used, including light and electron microscopy, various in vivo functional assays, and biochemical and biomechanical measurements. These data indicate that a lack of Col XV leads to cardiomyopathic changes that may predispose the subject to pathological responses under cardiac stress.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Transgenic Mice and Experimental Procedures
The investigation conformed to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) . Generation of the Col XV-deficient mouse line has been described earlier. 19 Studies on cardiac gravimetry, angiotensin (Ang) IIinduced hypertension, and telemetric measurement of blood pressure were performed with 129 SV inbred, age-matched wild-type (WT) and Col15a1 Ϫ/Ϫ female mice at ages of 4 to 11 months and an N -nitro-L-arginine methyl ester (L-NAME)-induced pressure loading experiment was performed with corresponding males. For the histological, transmission electron microscopy (TEM) and scanning electron microscopy analyses, echocardiography, intravital microscopy, and stiffness measurements, C57BL6 inbred WT mice at ages of 1, 5, and 12 months were used (nϭ5 group), together with age-matched Col15a1 Ϫ/Ϫ mice with a C57BL6 background. No differences in clinical appearance or histological phenotype were observed between the sexes or genetic backgrounds.
Cardiac Function, Histopathology, and Molecular Analyses
The echocardiographic examinations were performed as described previously. 20 Left ventricles (LVs) were prepared for histological and molecular analysis, including immunohistochemical, immunoelectron microscopy (IEM), TEM, and scanning electron microscopy analysis, RNA isolation, quantitative PCR and radioimmunoassay. Intravital microscopy was performed using dorsal skinfold chambers and cranial window preparations as described. 21 
Statistical Analysis
Statistical significance of difference between the group means were tested using Student's t test.
Results

Interstitial Accumulation of Nonfibrillar Protein Deposits, Disorganized Fibrillar Collagen Matrix, and Decreased Elasticity in the Col15a1 ؊/؊ Mouse LV
To investigate the morphological characteristics of the cardiac and microvascular ECM, LV samples from the Col15a1 Ϫ/Ϫ and WT mice were examined by TEM. In addition to the fibrillar collagen matrix, a small amount of nonfibrillar proteins was observed in the cardiac interstitium of the young WT mice (1 month of age), which was then reduced in amount during aging ( Figure 1A and 1C ). The nonfibrillar protein deposits were more readily detectable in Figure 1B ) and, in contrast to WT, accumulated during aging ( Figure 1D ). As indicated in IEM, the nonfibrillar protein deposits contained ECM and serum proteins, including fibronectin, Col VI, and fibrin (Online Figure I ). In the case of fibrin, increased perivascular staining was detected in the Col15a1 Ϫ/Ϫ by comparison with the WT LVs. The structure and distribution of the fibrillar collagen matrix was further studied using scanning electron microscopy, in which the fibrillar collagen bundles in the WT mice were seen to have formed characteristic waves and struts covering the cardiomyocytes ( Figure 1E ). In contrast to the well-organized pattern in WT, the fibrillar collagen bundles in the Col15a1 Ϫ/Ϫ endomysium were loose and disorganized (Figure 1F) . A lower proportion of thick collagen bundles in the Col15a1 Ϫ/Ϫ LV was also evident in picrosirius red-stained samples analyzed by polarized light microscopy (Online Figure II) . The mean green/red ratios (representing thin and thick collagen fibers, respectively) were 1.10Ϯ0.06 and 1.41Ϯ0.11 for WT and Col15a1 Ϫ/Ϫ , respectively (meansϮSEM, PϽ0.01), at age 5 months and 1.18Ϯ0.04 and 1.25Ϯ0.07 at 1 month (meansϮSEM, PϭNS). These data indicate that a lack of Col XV in the heart is not profibrotic under unstressed conditions, but rather that the fibrillar matrix is poorly organized in the absence of Col XV and contains marked interstitial deposition of nonfibrillar protein aggregates. Longitudinal analysis suggested an aging-dependent accumulation of nonfibrillar protein deposits and alteration in fibrillar collagen phenotypes.
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To test whether Col XV deficiency and observed changes in the matrix may affect cardiac elasticity, stiffness measurements were performed on the LVs of WT and Col15a1 Ϫ/Ϫ mice using a microprobe indenter device. Slices (2 mm) were indented in steps using a needle probe indenter, and the stiffness was calculated from plots of force versus indentation depth. The stiffness of the Col15a1 Ϫ/Ϫ LV, quantified by its Youngs modulus was 27.1Ϯ1.4 kPa, whereas the value in the WT mice was 21.4Ϯ2.3 kPa (meansϮSD, PϽ0.05), indicating an increase in myocardial stiffness in the Col15a1 Ϫ/Ϫ mice ( Figure 1G ). To verify this observation, we used liver as a softer and as a Col XV negative control tissue. 9 The WT and Col15a1 Ϫ/Ϫ mice had virtually equal stiffness in the liver, the mean force being 11.5Ϯ0.4 and 11.2Ϯ0.5 kPa (meansϮSEM, respectively).
Structural and Morphological Changes in Microvessels and Ischemic Damage in
Col15a1 ؊/؊ Cardiomyocytes TEM also revealed morphological changes in the heart capillaries, including irregular luminal shapes accompanied by endothelial cell degeneration and swelling, as described previously. 19 To study the microvessels in more detail, a scanning electron microscopy analysis was carried out. The capillaries in the WT mice showed intact surfaces, whereas in the mutant mice there were frequent ruptures in the capillary walls, observed in 10% to 20% of the capillaries analyzed (Figure 2A and 2B ). In addition, the mutant capillaries were tortuous and showed variations in thickness ( Figure 2C and 2D). The structural abnormalities detected by scanning electron microscopy were consistent with extravasated erythrocytes and ischemic damage in some of the cardiomyocytes, as revealed by TEM (Online Figure III, K and L). To investigate whether the vascular patterning and ruptures were associated with poor vascular maturity, including defective perivascular cell recruitment, LV were immunostained with antibodies to CD31 and NG2 to detect endothelial cells and pericytes, respectively. As observed in scanning electron microscopy, the vessel pattern in the Col15a1 Ϫ/Ϫ samples was disorganized with irregular alignment of the capillaries as compared with that in the WT mice, although the mutant microvessels showed a normal pericyte covering ( Figure 2E and 2F), suggesting normal maturation.
Quantification of the capillary density using histological sections stained with CD31 showed the Col15a1 Ϫ/Ϫ mice to have a 32% increase in capillary density compared with the WT (PϽ0.01) at 5 months of age ( Figure 2G ). The increased capillary number in Col15a1 Ϫ/Ϫ was found to be agedependent, because capillary densities were similar in the Col15a1 Ϫ/Ϫ and WT mice at age 1 month. In WT, the capillaries are aligned with the myocytes (C), whereas in Col15a1 Ϫ/Ϫ , they are tortuous and vary in thickness (D). Intact capillaries are marked with arrows in A through D, and ruptures in the capillaries with arrowheads. Vascular patterning and pericyte recruitment were studied using CD31-and NG2-stained LVs from WT (E) and Col15a1 Ϫ/Ϫ (F) mice. The double labeling shows that the pericytes (NG2, red) are covering the capillaries (CD31, green) in both the WT and Col15a1 Ϫ/Ϫ hearts. The vascular pattern is disorganized, however, and shows increased variation in the diameter and alignment of the microvessels in the Col15a1 Ϫ/Ϫ heart. G, The capillary density/microscopy field 0.06 mm 2 is higher in 5-month-old Col15a1 Ϫ/Ϫ (black bar) than in the WT (white bar) heart; at 1 month, no difference was seen between the genotypes. **PϽ0.01 (meansϮSEM).
To investigate the potential involvement of the aorta and coronary arteries in the Col15a1 Ϫ/Ϫ cardiac phenotype, WT tissue samples were first stained with Col XV antibodies. In contrast to the endothelial BM location in capillaries, Col XV was found to be located in the outermost connective tissues layer in the aorta (tunica adventitia) and in the coronary arteries (Online Figure III , A through D). The lack of Col XV immunoreactivity in the endothelial BM in WT was in line with the observation that the endothelial cell layer in the Col15a1 Ϫ/Ϫ arteries and aorta was intact (Online Figure III, E through H). Moreover, levels of Bnip-3 and Glut-1 mRNAs, known markers of an ischemic myocardium attributable to coronary artery occlusion, 22, 23 were not altered between the genotypes (Online Figure III , I and J). These data suggested an important role for Col XV in the capillary BM underlying the endothelial cell lining. The defect in capillary structure was not sufficient to induce marked ischemic damage at the level of the whole LV, however.
Microvascular Dysfunction Attributable to Lack of Col XV
The observed morphological alterations suggested dysfunctional microvessels in the Col15a1 Ϫ/Ϫ mice. Our previous immunostaining studies have indicated that in adults, Col XV is deposited around the capillaries in specific vascular beds, including the heart and the skin. 9 To investigate microvascular function in vivo, intravital microscopy, which readily allows analysis of the superficial vasculature, as in the skin and brain, was used in living mice. A decrease in the capillary perfusion index ( Figure 3A) , reduced red blood cell velocity ( Figure 3B ), and a lower microvascular blood flow rate ( Figure 3C ) were observed in the Col15a1 Ϫ/Ϫ skin, indicating decreased microcirculatory function. Furthermore, increased microvascular permeability was observed in the Col15a1 Ϫ/Ϫ mice ( Figure 3D ). The quantified results regarding capillary density in the skin show no differences between the WT and Col15a1 Ϫ/Ϫ mice ( Figure 3E ). Because previous studies have indicated that Col XV occurs in only a few capillaries in the adult brain, 9 we decided to use the brain as a control for the hemodynamic abnormalities observed in the Col15a1 Ϫ/Ϫ skin. As expected, lack of Col XV did not alter the functional parameters of the cerebral microcirculation, as visualized through the cranial window (Online Figures IV and V).
Cardiac Hypotrophy in Aged Col15a1 ؊/؊ Mice
To investigate the changes in cardiac structure further, we followed the cardiac mass during aging from 19 to 78 weeks ( Table 1 ). In the young (average age, 7 months) and middleaged (11 months) Col15a1 Ϫ/Ϫ mice, the LV and total heart mass and their ratio to body weight were unchanged relative to the WT mice, but in the older mice (16 months), the cardiac weights were found to be lower in the Col15a1 Ϫ/Ϫ than in the WT mice.
Echocardiography and Telemetric Measurement of Blood Pressure in WT and Col15a1 ؊/؊ Mice
We used echocardiographic and telemetric analysis to investigate cardiac structure and function, heart rate, and blood pressure in living mice. Echocardiography ( Table 2 and Online Figure IX) confirmed the smaller cardiac size in aged Col15a1 Ϫ/Ϫ mice. This was associated with thinner interventricular septum and posterior wall of the Col15a1 Ϫ/Ϫ LV than in the WT mice. However, no differences in LV volume or in systolic or diastolic function were observed between the Col15a1 Ϫ/Ϫ and WT mice at the age of 14 months. For a longitudinal view, cardiac function was analyzed in 1 and 7 months. Systolic dysfunction was observed in the juvenile Table I and Online Figure IX) . These abnormalities in heart function and dimensions in the Col15a1 Ϫ/Ϫ mice were substantially improved at the age of 7 months, however (Online Table I and Online Figure IX) . Collectively, echocardiographic analysis revealed an early-onset cardiac phenotype suggestive of DCM, recovery of LV function and geometry with time, and age-dependent thinning of the LV wall in Col15a1 Ϫ/Ϫ mice.
Telemetric measurement revealed that the blood pressure did not differ between the null mice and the WT littermates (mean arterial pressures: 107Ϯ12 and 107Ϯ9 mm Hg, WT and Col15a1 Ϫ/Ϫ mice, respectively, meansϮSEM).
Alterations in Cellular Architecture and Intercalated Discs in Col15a1 ؊/؊ LVs
Several mechanisms for ventricular thinning have been proposed, such as myocyte loss and atrophy, and alterations in cellular architecture, including an increase in length, variability in size, and lateral slippage of cardiomyocytes, leading to cellular misalignment. 5 Therefore, the cellular mechanisms that may underlie the thinner LV wall in the Col15a1 Ϫ/Ϫ mice were investigated further by measuring the numbers of cardiomyocytes and their dimensions (diameter, length, and shape).
No statistically significant difference in cell density (61.0Ϯ4.7 cells per field for Col15a1 Ϫ/Ϫ versus 59.8Ϯ6.3 for WT) or myocyte diameter (14.79Ϯ1.4 versus 14.82Ϯ1.3 m) was observed ( Figure 4B) , indicating that the thinner Col15a1 Ϫ/Ϫ LV in the old mice (12 to 14 months) does not result from smaller cell size. Instead, the Col15a1 Ϫ/Ϫ LV in the 1-month-old mice ( Figure 4A ) showed decreased cardiomyocyte diameters (11.8Ϯ0.2 m) relative to WT (12.5Ϯ0.1 m, meansϮSEM, PϽ0.01), but no change in cell density (93.0Ϯ4.5 and 93.0Ϯ4.0 cells per field, respectively).
To study the cellular organization of the cardiomyocytes, 50-m LV sections were stained with laminin ␤2 (BMs) and N-cadherin (intercalated discs) to visualize the lateral sides of single myocytes and their cell-cell junctions, followed by optical sectioning with confocal microscopy. No change in the number of intercalated disks was observed between the genotypes ( Figure 4C ) in the old mice (12 to 14 months); however, Col15a1 Ϫ/Ϫ intercalated discs were shorter (42.7Ϯ2.9 m as compared with WT 52.8Ϯ2.2 m, meansϮSEM, PϽ0.05; Figure 4D ), fragmented, and unevenly distributed along the cardiomyocytes ( Figure 4E and  4F) . Moreover, the cardiomyocytes in the Col15a1 Ϫ/Ϫ samples were found to be irregularly shaped and elongated (Online Figure VI) . For comparison, cellular organization was studied in juvenile mice at the age of 1 month. The spatial organization of cardiomyocytes was normal in the Col15a1 Ϫ/Ϫ individuals, although the cardiomyocytes were shorter than in WT (187.0Ϯ4.9 versus 210.4Ϯ4.0 m for WT, meansϮSEM, PϽ0.001). In addition, at this age, the Col15a1 Ϫ/Ϫ mice had shorter intercalated discs (39.04Ϯ0.37 versus 42.83Ϯ0.38 m in WT, meansϮSEM, PϽ0.001, Figure 4D ). Ultrastructural analysis revealed fragmented and irregular intercalated discs, specifically adherence junctions exhibited disarrangement of filaments in the Col15a1 Ϫ/Ϫ LVs as opposed to the continuous, well-defined intercalated disc and adherens junctions in the WT (Figure 4G and 4H) . These data indicate that the early-onset defects (at age 1 month) attributable to a lack of Col XV included smaller cardiac myocytes and shorter intercalated discs. Interestingly, a reversal in cardiomyocyte size was concurrent with an improvement in cardiac function and dimensions and increase in capillary density, whereas altered cellular organization of the cardiomyocytes emerge with increasing age.
Increased Expression and Ultrastructural Localization of Col XV in Normal and Hypertensive LVs
To study the Col15a1 Ϫ/Ϫ and WT cardiovascular systems under acute loading conditions, we next used 2 wellcharacterized models for experimental hypertension, namely Ang II-induced pressure overload and nitric oxide (NO) inhibition with L-NAME. In addition to raising the peripheral resistance through vasoconstriction, Ang II also exhibits direct hypertrophic effects on cardiomyocytes 24 and has marked profibrotic effects in the heart, 25 whereas L-NAME primarily induces sustained systemic arterial hypertension by inhibiting NO synthesis in vascular endothelial cells. 26 To gain insights into the role of Col XV in experimental hypertension, we first measured its expression in shamoperated and loaded WT mice. The LV Col XV/18S RNA ratio was elevated 3.2Ϯ0.4-fold after a 3-day Ang II treatment (PϽ0.001 versus sham; Figure 5A ), whereas L-NAME increased the LV Col XV/18S RNA ratio 1.34Ϯ0.09-and 1.87Ϯ0.10-fold after 3 days and 2 weeks of treatment, respectively, as compared with sham-operated control mice (PϽ0.05 and PϽ0.001 versus sham; Figure 5B ). Ultrastructurally, Col XV accumulated along the fibrillar collagens in the ECM and in the nonfibrillar proteins between the cardiomyocytes and endothelial cells ( Figure 5C and 5D ). These data indicated that expression of Col XV is upregulated under hypertensive conditions and that it is deposited in the interstitium and associated with the fibrillar collagen matrix.
Growth Responses in Col15a1 ؊/؊ Hearts Under Hypertensive Conditions
Because the fact that Col15a1 Ϫ/Ϫ cardiac weight did not follow the WT pattern in an unstressed state (Table 1) could be attributable to either a lack of sufficient growth stimuli or low responsiveness to the stimuli, we tested cardiac growth responses under hypertensive conditions following Ang II and L-NAME loading. Three days of Ang II treatment increase in the LV/body weight ratio in the WT mice by 55Ϯ4% (meansϮ SD), and a comparable increase, 54Ϯ6%, was observed in the Col15a1 Ϫ/Ϫ mice ( Figure 6A ). Furthermore, an increase in LV/body weight was observed after 3 days of L-NAME treatment in both Col15a1 Ϫ/Ϫ and WT mice (3Ϯ2% and 3Ϯ3%), and values remained elevated at 2 weeks (10Ϯ4% and 10Ϯ3%, WT and Col15a1 Ϫ/Ϫ mice, respectively) ( Figure 6A ). Cardiac dimensions and function under hypertensive conditions were investigated by means of echocardiographic measurements (Table 2) . Consistent with the gravimetric data, an increase in LV weight was evident in the Col15a1 Ϫ/Ϫ mice as compared with the WT mice, the change from the baseline being even higher in the Col15a1 Ϫ/Ϫ mice than in the WT ones. This indicated that although cardiac weight in the Col15a1 Ϫ/Ϫ mice did not follow the normal pattern of development during aging, they reacted normally to a hypertrophic stimulus, ie, cardiac expression of Col XV is not necessary for hypertrophic responses. 
Effects of Experimental Hypertension on Markers of Cardiac Loading
To investigate cardiac loading and hypertrophic responses in more detail, we measured mRNA levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), widely used markers of stretch-induced cardiac loading. 27 The ratios of ANP mRNA (0.13Ϯ0.02 and 0.16Ϯ0.02 in WT and Col15a1 Ϫ/Ϫ , respectively, meansϮSEM) and BNP mRNA to 18S mRNA (0.25Ϯ0.05 and 0.28Ϯ0.04 in WT and Col15a1 Ϫ/Ϫ , respectively, meansϮSEM) did not differ significantly between the unstressed WT and Col15a1 Ϫ/Ϫ mice ( Figure 6B and 6C) . Three-day treatment with Ang II led to 21.0Ϯ2.0-and 11.7Ϯ1.8-fold induction of the ANP and BNP mRNAs relative to 18S mRNAs in the LVs of the WT mice, whereas the induction of ANP and BNP gene expression in the Col15a1 Ϫ/Ϫ mice was attenuated by 30Ϯ7% and 47Ϯ6%, respectively, relative to WT (Figure 6B and 6C) . To compare ANP and BNP protein levels, LV homogenates from shamand Ang II-treated WT and Col15a1 Ϫ/Ϫ mice were measured by RIA. The assay revealed a correlation between BNP mRNA and protein levels but not between ANP mRNA and protein after 3 days of Ang II treatment (Online Figure VII) . This result is consistent with the differential regulation and storage of the peptides. 28 These findings suggest that Ang II induces different loads in Col15a1 Ϫ/Ϫ than in WT mice, or that Col15a1 Ϫ/Ϫ hearts are unable to respond to Ang II-induced loading in the normal way. To test for equal loading, ␣-SKA mRNA levels were measured, 29 and were found to be similar at the basal level (␣SKA mRNA to 18S mRNA 0.10Ϯ0.01 and 0.11Ϯ0.02 in WT and Col15a1 Ϫ/Ϫ , respectively, meansϮSEM) and to be elevated to the same degree in both in response to Ang II ( Figure 6D ).
Experimental Hypertension Leads to an Altered ECM Response in Col15a1 ؊/؊ Mice
The observed induction of Col XV expression and its accumulation after a hypertrophic stimulus in the outermost layer of the BM and in the interstitial collagen fibers near the BMs (Figure 5D ), combined with the morphological alterations observed in the fibrillar collagen matrix ( Figure 1E and 1F) , suggested a role for Col XV in fibrillar matrix remodeling. To ascertain whether the ultrastructural changes observed in unstressed mice are associated with altered expression of fibrillar collagens, and whether Col XV deficiency predisposes the individual to fibrosis under loading conditions, we measured Col I and Col III mRNAs, which represent the most abundant ECM proteins in the heart and are hence widely used as markers of cardiac fibrosis. 30 We also examined the ratio between them, as an indicator of myocardial stiffness and a marker of cardiac dysfunction. 31 The mRNA levels of Col I (ratio of Col1a1 mRNA to 18S mRNA: 0.29Ϯ0.05 and 0.30Ϯ0.05 in WT and Col15a1 Ϫ/Ϫ , respectively) and Col III (ratio of Col3a1 mRNA to 18S mRNA; 0.19Ϯ0.02 and 0.22Ϯ0.03 in WT and Col15a1 Ϫ/Ϫ , respectively, meansϮSEM) were similar in the 2 groups at the basal level ( Figure 6E ). Although both Col I and Col III expression was induced in the Ang II-treated WT and Col15a1 Ϫ/Ϫ mice, the induction of Col III expression was blunted in Col15a1 Ϫ/Ϫ when compared to WT mice ( Figure 6E ), leading to an abnormally increased Col I/III ratio. Consistent with the mRNA data, collagen staining with picrosirius red analyzed by bright field microcopy did not reveal any quantitative differences in total fibrillar collagen content between the Col15a1 Ϫ/Ϫ and WT hearts at the basal level or after 2 weeks of Ang II treatment (Online Figure VIII , A through D). Nevertheless, picrosirius red staining followed by polarized light microscopy demonstrated a striking qualitative difference in the collagen phenotype between the genotypes after Ang II treatment (Online Figure VIII, K) , with a slight increase in the green/red ratio (small/large fibrils) in the WT mice relative to sham (ϩ10.5Ϯ7.5%), whereas in the Col15a1 Ϫ/Ϫ mice, this ratio decreased (Ϫ30.3Ϯ2.6%, meansϮSEM, PϽ0.001). In contrast to the total amount of fibrillar collagens, accumulation of the nonfibrillar protein (Online Figure VIII , E through J) was strongly induced in the Col15a1 Ϫ/Ϫ hearts after Ang II treatment. Collectively, these findings suggest that Col XV plays a role in matrix remodeling in the heart and participates in the organization of the collagen fibrils. Furthermore, in terms of quality of the fibrillar collagen matrix, the Col15a1 Ϫ/Ϫ mice responded abnormally to increased hemodynamic loading, which may predispose a subject to pathological responses under cardiac stress.
Discussion
Our characterization of the structural and in vivo cardiovascular properties of the nonfibrillar collagen XV in null mice under basal conditions and after experimental hypertension led to the following novel findings. (1) Col XV is necessary for organization of the fibrillar collagen matrix in cardiac muscle. This observation significantly extends our understanding of the physiological functions of Col XV and reveals an unexpected role in cardiac pathophysiology. (2) Col XV is required for proper circulation in specific microvascular beds. The data point to a specific role for Col XV in the subendothelial BM of capillaries. (3) Despite the reduced complexity of the fibrillar collagen matrix, lack of Col XV unexpectedly increased myocardial stiffness. Higher-order molecular assemblies of Col XV are known to differ significantly from fibrillar collagens, and our findings suggest these may enhance tissue resilience. (4) There is an atypical presentation of distinct cardiomyopathic indications in juvenile and old Col XV-deficient mice. This suggests that the significance and/or functions of Col XV assemblies may differ during the postnatal period and in the aging heart. (5) Different responses to experimental hypertension were observed in the Col15a1 Ϫ/Ϫ relative to the WT mice. These included blunted induction of natriuretic peptide mRNAs and qualitatively different fibrotic lesions. It should be noted that the physiological analyses were performed with females and the parameters were not compared with those in male mice, which, in other cases, have shown a more severe cardiac phenotype, 6 and also that no mice older than 14 months were available for physiological observations. Nevertheless, these data clearly indicate that Col XV plays an important role in cardiovascular pathologies.
Echocardiograms indicated that the changes in cardiac performance and geometry in the Col15a1 Ϫ/Ϫ mice varied with age. Dilated LVs and decreased EF and FS were observed in juveniles (1-month-old), whereas LV wall thinning was found in aged mice (14 month) . This, surprisingly, indicated that some of the early-onset defects in Col15a1 Ϫ/Ϫ mice may be reversible. The exact mechanisms underlying recovery are not known, but improvement in systolic function and dimensions was concurrent with normalized cardiomyocyte diameter and an increase in capillary density. Although the Col15a1 Ϫ/Ϫ microvessels were found to be abnormal, we propose that the increase in their number may be sufficient to restore cardiac performance. Certain histopathologic alterations were present at all ages analyzed, namely leaky capillaries and structural changes in the extracellular space. We propose that these changes represent the primary ECM defect attributed to lack of Col XV and that these may occur independently from poor perfusion of dysfunctional microvessels. The data also suggested that Col XV may have different roles during the postnatal period of heart development and in the aged heart. This scenario is supported by the observations that Col XV expression in the myocardium is developmentally regulated, as the whole thickness of the LV stains for Col XV at a relatively late developmental stage, at embryonic day 18.5, 9 and that the cardiac ECM differs between young and old individuals. 32 Considering the typical presentations of human cardiomyopathies, the Col15a1 Ϫ/Ϫ phenotypic changes resemble best those found in mildly symptomatic or asymptomatic relatives of DCM patients. DCM is usually diagnosed by echocardiography on the basis of LV dilatation and a reduction in systolic function in the absence of significant hypertension or coronary artery disease. 33 LV dysfunction is typically progressive because of continuous maladaptive remodeling, rendering DCM the most frequent cause of heart transplantation. 33 However, recent studies have indicated that DCM may manifest itself clinically, with a wide age range and highly variable phenotypes, and that asymptomatic or mildly symptomatic relatives can be identified in family screening studies. 34 -36 The subjects may have a moderate enlargement in LV dimensions in either the diastole or systole, and depressed FS. These echocardiographic parameters can only predict the development of DCM to a limited extent, and no widely accepted criteria exist for the definition or recognition of preclinical DCM. [35] [36] [37] [38] [39] Echocardiography revealed certain characteristics of DCM in juvenile Col15a1 Ϫ/Ϫ mice, namely increased LV volume and depressed EF and FS, albeit this condition was not progressive, in contrast to the classic presentation of DCM. No clear evidence for hypertension or coronary artery disease was found in the Col15a1 Ϫ/Ϫ mice.
As in the Col XV-deficient mice, a bimodal pattern of clinical presentation is observed in certain inherited forms of DCM. This is especially evident in a recent extensive study demonstrating that a mutation in the ␣-tropomyosin gene can cause either severe symptoms in early life or mild asymptomatic LV dilation in adulthood. 34 In these families, a subset of affected infants showed an improvement in LV contractility, which was unlikely to be related solely to receiving basic medical therapy. 34 Additionally, in follow-up studies of mildly affected DCM family members and in rare cases of patients with acute/recent onset idiopathic DCM improvements in cardiac function with time have been documented. 40 -42 The mechanisms underlying improved cardiac function in some patients and distinct age-dependent clinical manifestations are currently unknown.
Our cellular and molecular studies of the Col15a1 Ϫ/Ϫ mice also revealed abnormalities in the myocardium associated with DCM occurring without or before the depression of cardiac function. These included poorly organized collagen bundles, 43 abnormalities in intercalated disks, 5 irregularly organized cardiomyocytes, 44, 45 increased myocardial stiffness, 46, 47 and dysfunctional microcirculation. 48, 49 Collectively, these data indicate that a lack Col XV leads to a complex cardiac phenotype that may predispose to cardiomyopathy.
Despite reduced complexity of the fibrillar collagen matrix, a modest increase in myocardial stiffness was observed in the Col15a1 Ϫ/Ϫ LVs. In view of the location of Col XV in around the cardiomyocytes, and taking into account its proposed "molecular shock absorber" role, 14 we suggest that Col XV may modulate the elasticity of myocardium. Hence, lack of this protein may directly explain the increase in myocardial stiffness in deficient mice. Ultrastructural analysis revealed accumulation of nonfibrillar protein deposits in the Col15a1 Ϫ/Ϫ cardiac interstitium. This was predominant in the perivascular areas was strongly induced in the Col15a1 Ϫ/Ϫ hearts after Ang II treatment and accumulated during aging. The candidate protein screening did not reveal any single major constituent, but rather suggested that the deposits are attributable to leakage of plasma proteins from the damaged capillaries. This accumulation may also represent an immature ECM in the growing cardiac muscle. The effect of the deposit on the properties of the myocardium is currently unclear, but it is conceivable that such protein accumulation may also be sufficient to alter the elasticity of the cardiac muscle, in a similar manner to amyloidosis, storage diseases and hemochromatosis in restrictive cardiomyopathies.
Experimental models for hypertension were used to test the responses to an increased cardiovascular load in terms of hypertrophy, cardiac loading, and development of fibrotic lesions. ANP and BNP mRNAs, markers of stretch-induced cardiac loading, were attenuated in Col15a1 Ϫ/Ϫ relative to WT mice, although the increase in LV weight and in the expression of ␣SKA and Col I did not differ between the genotypes, indicating equal loading. We also observed blunted Col III expression in the Col15a1 Ϫ/Ϫ mice under hypertensive conditions and, as a consequence, an abnormally increased Col I/III mRNA ratio. This has been reported to serve as an indicator of myocardial stiffness and a marker of cardiac dysfunction, as a predominance of Col I increases stiffness, whereas a higher proportion of Col III increases tissue elasticity. 31 In addition, picrosirius red staining followed by polarized light microscopy demonstrated a qualitative difference in collagen phenotype between the genotypes at the basal level and after hypertensive conditions. The ECM is a major determinant of the structural integrity and mechanical properties of the myocardium under physiological conditions and plays a central role in cardiac remodeling in response to cardiovascular loading. 1, 2 Although this remodeling can initially be regarded as a compensatory response, the changes in the quantity and quality of the cardiac ECM may gradually lead to ventricular dysfunction and heart failure. The molecular mechanisms underlying the early phases of cardiac remodeling, before any apparent clinical phenotype has arisen, have been poorly elucidated so far and no mouse model exists for such studies. When assessing the clinical relevance of the findings reported here we conclude that: (1) COL15A1 should be considered as a new candidate gene for involvement in human familial cardiomyopathies. The identification of novel gene products that may modify cardiovascular functions is important for understanding the pathophysiology of heart diseases and the early identification of patients at risk. Intriguingly, the gene encoding human Col XV has been mapped to the genomic region 9q21-22, 50 which is within the chromosomal region 9q13-q22 reported to contain an unidentified disease-causing gene for familiar DCM. 51 (2) In addition to the cardiovascular system, Col XV is expressed in the BM zones of other organs 9 (eg, kidneys, peripheral nerves, and skeletal muscle). The findings reported here may have important implications for various other common disease states, such as fibrotic diseases or restrictive pathophysiologies, or in the development of other vascular disorders, such as atherosclerosis or diabetes. In further studies, it will also be possible to determine whether lack of Col XV predisposes to cardiomy-opathy under ischemic conditions or a progression from viral myocarditis to DCM. (3) The natural history of the cardiac phenotype attributable to a lack of Col XV is unusual, showing decreased LV performance in juvenile mice and functional recovery in older mice. Identification of the mechanism(s) related to the improvement in cardiac contractility would be of great value, probably leading to a better understanding of the pathophysiology of cardiomyopathies and potentially to the development of new therapies.
